Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Genmab A/S filings document the company’s reporting as a foreign private issuer and its formal company announcements on antibody-medicine operations, financial results, governance and share capital. Recent Form 6-K reports include interim financial information, DARZALEX® royalty-related sales disclosures from Johnson & Johnson, pipeline commentary for EPKINLY®, Rina-S® and petosemtamab, and updates incorporated by reference into Form S-8 registration statements.
The filing record also documents Danish-market disclosure matters, including major shareholder notifications, managerial transactions in shares and linked securities, amendments to the articles of association, and registered share capital reductions. These filings provide the formal record for Genmab’s capital structure, ownership notifications, governance documents and recurring biotechnology business disclosures.
Genmab A/S has filed a Form 6-K to furnish a company announcement stating that it plans to acquire Merus. The announcement highlights that the deal is intended to expand Genmab’s late-stage drug pipeline and accelerate a shift toward a wholly owned product model, meaning Genmab aims to control more of its future medicines rather than relying mainly on partnerships.
The Form 6-K is also designated to be incorporated by reference into several existing Genmab registration statements on Form S-8, so the information in this report becomes part of those employee share incentive-related filings.
Genmab A/S filed a Form 6-K as a foreign private issuer for September 2025. The filing notes that a company announcement dated September 26, 2025 covers the grant of restricted stock units and warrants to employees of Genmab.
The Form 6-K is deemed incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the information in this report becomes part of those employee equity compensation-related registrations from the filing date, unless later superseded by other filings.
Genmab A/S has furnished a Form 6-K for September 2025 that attaches two exhibits related to a major shareholder. The exhibits are a company announcement dated September 23, 2025 and a standard notification of major holdings. The filing is incorporated by reference into Genmab’s existing Form S-8 registration statements.
Genmab A/S submitted a Form 6-K for September 2025 that attaches two company announcements dated September 9, 2025. One announcement describes a capital increase in Genmab resulting from employee warrant exercises. The other details transactions in Genmab shares and linked securities by managerial employees and their closely associated persons.
The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, making these announcements part of those share-based compensation plans’ disclosure record.
Genmab A/S filed a Form 6-K as a foreign private issuer for August 2025. The report primarily forwards an attached company announcement describing a capital increase in Genmab resulting from the exercise of employee warrants. The filing also specifies that this 6-K is incorporated by reference into several existing Genmab Form S-8 registration statements covering employee equity compensation plans.
Genmab’s H1-25 6-K shows solid growth and an upgraded FY-25 outlook. Revenue climbed 19 % YoY to $1.64 bn on stronger DARZALEX (+22 % J&J sales), Kesimpta and EPKINLY. Royalty income rose 24 % to $1.38 bn, representing 84 % of total revenue. Operating profit increased 56 % to $548 m as costs grew only 6 %, expanding the margin to 33 %. Net profit reached $531 m.
Liquidity remains robust with $1.30 bn cash and $1.60 bn marketable securities; equity ratio is 82 %. Functional and presentation currency switched to USD on 1 Jan 25.
Revised 2025 guidance: revenue $3.5-3.7 bn (mid-point +$100 m), operating profit $1.055-1.405 bn (mid-point +$100 m); operating-expense range unchanged.
Operational highlights: sBLA filed for epcoritamab+R2 in r/r FL; Tivdak launched in Japan; Rina-S posted 50 % ORR in endometrial cancer; >40 epcoritamab abstracts presented. Workforce up to 2,639 FTEs.
Risks & negatives: TEPEZZA royalties -8 %; lower reimbursement revenue; ongoing Chugai patent suit and AbbVie trade-secret litigation; FX gains moderated after USD switch.